FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease

American Journal of Hematology

Volumn 85, Issue 5, 2010, Pages 315-319

  Lu, Min ^a   Cohen, Martin H ^a   Rieves, Dwaine ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERAHEME; FERUMOXYTOL; IRON; TRANSFERRIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ANAPHYLAXIS; ARTICLE; BACKACHE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; FEVER; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTENSION; IRON DEFICIENCY ANEMIA; IRON THERAPY; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MUSCLE SPASM; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL EDEMA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; THORAX PAIN; URTICARIA; VOMITING; WHEEZING;

ADMINISTRATION, ORAL; ANEMIA, IRON-DEFICIENCY; DRUG APPROVAL; DRUG HYPERSENSITIVITY; FEMALE; FERROSOFERRIC OXIDE; FERROUS COMPOUNDS; HEMATINICS; HEMOGLOBINS; HUMANS; HYPOTENSION; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED;

EID: 77951619720     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21656     Document Type: Article

References (33)

1. Levey A, Eckardt K, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005;67:2089-2100. (Pubitemid 41623371)
2. Kalantar-Zadeh K, Streja E, Miller JE, Nissenson AR. Intravenous iron versus erythropoiesis-stimulating agents: Friends or foes in treating chronic kidney disease anemia? Adv Chronic Kidney Dis 2009;16:143-151.
3. Hörl WH. Comparing the efficacy of intravenous iron and oral iron in non-dialysis patients with chronic kidney disease. Nat Clin Pract Nephrol 2008;4: 530-531.
4. Hudson JQ, Comstock TJ. Considerations for optimal iron use for anemia due to chronic kidney disease. Clin Ther 2001;23:1637-1671.
5. National Kidney Foundation. K/DOQI clinical practice guidelines and clinical practice recommendations for anemia of chronic kidney disease, 2006. Am J Kidney Dis 2006;47 (Suppl 3):S11-S145.
6. Wish JB. Assessing iron status: Beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006;1 (Suppl 1):S4-S8.
7. Nissenson AR, Strobos J. Iron deficiency in patients with renal failure. Kidney Int Suppl 1999;69:S18-S21. (Pubitemid 29113579)
8. Fishbane S. Anemia in chronic kidney disease: Status of new therapies. Curr Opin Nephrol Hypertens 2009;18:112-115.
9. Larson K. IV iron use in patients with higher serum ferritin: Case study on anemia in kidney disease. Nephrol Nurs J 2008;35:184-193.
10. Macdougall IC. Strategies for iron supplementation: Oral versus intravenous. Kidney Int Suppl 1999;69:S61-S66. (Pubitemid 29113585)
11. Agarwal R, Warnock D. Issues related to iron replacement in chronic kidney disease. Semin Nephrol 2002;22:479-487. (Pubitemid 35351260)
12. Rozen-Zvi B, Gafter-Gvili A, Paul M, et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: Systematic review and meta-analysis. Am J Kidney Dis 2008;52:897-906.
13. Ozment CP, Turi JL. Iron overload following red blood cell transfusion and its impact on disease severity. Biochim Biophys Acta 2009;1790:694-701.
14. Bullen JJ, Rogers HJ, Spalding PB, Ward CG. Iron and infection: The heart of the matter. FEMS Immunol Med Microbiol 2005;43:325-330.
15. Espósito BP, Breuer W, Slotki I, Cabantchik ZI. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest 2002;32 (Suppl 1):42-49. (Pubitemid 41704987)
16. Hayat A. Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. Clin Med Res 2008;6:93-102.
17. Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004;65:2279-2289. (Pubitemid 38670014)
18. Agarwal R, Rizkala AR, Kaskas MO, et al. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. Kidney Int 2007;72:638-642. (Pubitemid 47312801)
19. Auerbach M. Ferumoxytol as a new, safer, easier-to-administer intravenous iron: Yes or no? Am J Kidney Dis 2008;52:826-829.
20. Balakrishnan VS, Rao M, Kausz AT, et al. Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur J Clin Invest 2009;39: 489-496.
21. Singh A, Patel T, Hertel J, et al. Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis 2008;52:907-915.
22. Provenzano R, Schiller B, Rao M, et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 2009;4:386-393.
23. Jacobs P, Johnson G. Wood L oral iron therapy in human subjects, comparative absorption between ferrous salts and iron polymaltose. J Med 1984;15:367-377. (Pubitemid 15006117)
24. Wingard RL, Parker RA, Ismail N, Hakim RM. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 1995;25:433-439.
25. Hsu CY, Mcculloch CE, Curhan GC. Iron status and hemoglobin level in chronic renal insufficiency. J Am Soc Nephrol 2002;13:2783-2786.
26. Silverberg DS, Blum M, Agbaria Z, et al. Intravenous iron for the treatment of predialysis anemia. Kidney Int Suppl 1999;69:S79-S85. (Pubitemid 29113588)
27. Folkert VW. Intravenous iron therapy in chronic kidney disease and peritoneal dialysis patients. Nephrol Nurs J 2003;30:571-576; 584.
28. Austrian Multicenter Study Group of r-HuEPO in Predialysis Patients. Effectiveness and safety of recombinant human erythropoietin in predialysis patients. Nephron 1992;61:399-403.
29. Koch KM, Koene RA, Messinger D, et al. The use of epoetin beta in anemic predialysis patients with chronic renal failure. Clin Nephrol 1995;44:201-208.
30. Silverberg DS, Iaina A, Peer G, et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 1996;27:234-238. (Pubitemid 26055136)
31. Domrongkitchaiporn S, Jirakranont B, Atamasrikul K, et al. Indices of iron status in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 1999;34:29-35. (Pubitemid 29318792)
32. Hörl WH. Iron therapy for renal anemia: How much needed, how much harmful? Pediatr Nephrol 2007;22:480-489.
33. Auerbach M, Al Talib K. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease. Kidney Int 2008;73:528-530. (Pubitemid 351264124)